Deerland Probiotics & Enzymes (Kennesaw, GA) has announced its acquisition of Bifodan A/S. Bifodan, based in Hundested, Denmark, is a life science company specialized in developing, manufacturing and distributing unique probiotic product solutions as private label dietary supplements, medical devices and OTC (over-the counter) drugs.
Effective with the acquisition, Bifodan is now a wholly owned subsidiary of Deerland Probiotics & Enzymes, Inc. Deerland’s Scott Ravech will continue in his role as CEO with global oversight of the newly combined company. Bifodan’s current CEO, Steen Andersen, has been named president of Deerland Probiotics and Enzymes International for the combined company and will be responsible for the Hundested site and all activities outside the Americas.
“We believe this investment will allow us to bring even greater value to our respective customers and to the enzyme and probiotic industries we serve,” said Ravech. Deerland and Bifodan are both focused on providing innovative, scientifically sound formulation and development services.
“We are excited to join the Deerland organization and have great expectations to leverage the combined competencies of our companies to create a strong global player,” stated Andersen.
The acquisition of Bifodan gives Deerland a larger global footprint, and highlights the company’s commitment to its vision for all people of all cultures to benefit from its enzyme, probiotic and prebiotic health products. “Deerland and Bifodan are leaders in their respective markets. Bringing together this expertise will benefit both companies, our employees, and our customers,” Ravech said.
For more information,visit www.deerland.com.
